Compare GE Vernova Inc (GEV) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Humana Inc — how do they compare? GE Vernova Inc trades at $1,004.73 (market cap $266.16B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: GE Vernova Inc is far larger — about 5.7× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Humana Inc for 51 Days on average.
| GEV | HUM | |
|---|---|---|
Market Cap | $266.16B | $46.49B |
Volume | 2,324,165 | 2,567,704 |
Sector | Industrials | Health |
52-Week High | $1.17K | $409.85 |
52-Week Low | $547.96 | $163.67 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $255.83B | $53.84B |
Dividend Yield | 0.2% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net margin, though valuation metrics appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent news highlights the company securing the first US construction permit for its BWRX-300 small modular reactor and benefiting from AI-driven power demand growth.
GEV presents growth potential from its $176 billion backlog and AI infrastructure demand, but faces valuation concerns and execution risks in its wind power segment. Analyst consensus remains strongly bullish with 75.86% buy ratings and $1,270 price target, representing 27% upside from current levels. Key risks include competitive pressures and the challenge of maintaining current premium valuation multiples.
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
